Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

Boulevard Bio has launched with $65 million in backing from Deerfield to develop a pipeline of three immunology drugs. The company is advancing the bispecific antibody BLVD101, which is currently undergoing a Phase 1 clinical trial. Founders include Schett, a researcher in immune reset, with technical support from AlivaMab Biologics and Ablexis. The capital injection marks a transition for the startup from stealth to active drug development.

Outlets like Fierce Biotech and Endpoints News note the company’s intent to address IgAN treatments, specifically targeting a treatment schedule of once every quarter. The firm is positioning its platform to compete with existing approaches in the autoimmune space. Reporting varies on the specific scope of the three drugs in the company's portfolio. While some sources characterize the pipeline as a targeted set of autoimmune therapies, others explicitly link the company’s strategic ambitions to the IgAN drug market currently occupied by Vera.

The exact technological limitations and the potential for off-target effects of the bispecific antibodies are not currently documented in available reports. Specific clinical milestones beyond the ongoing Phase 1 trial for BLVD101 have not been outlined. While the funding total is established, the timeline for the remaining two immunology candidates is not stated. Whether the company will prioritize internal development or seek additional strategic partnerships for its platform is not specified.